Moderna (NASDAQ:MRNA) Stock Rating Reaffirmed by Evercore ISI

Moderna (NASDAQ:MRNA)‘s stock had its “in-line” rating reissued by equities researchers at Evercore ISI in a note issued to investors on Thursday, Benzinga reports. They currently have a $120.00 price target on the stock. Evercore ISI’s price objective points to a potential upside of 1.05% from the company’s previous close.

A number of other brokerages have also weighed in on MRNA. Jefferies Financial Group reaffirmed a “buy” rating and issued a $125.00 target price on shares of Moderna in a research note on Tuesday, April 9th. Canaccord Genuity Group increased their price objective on shares of Moderna from $91.00 to $106.00 and gave the stock a “hold” rating in a research note on Friday, May 3rd. UBS Group increased their price objective on shares of Moderna from $143.00 to $151.00 and gave the stock a “buy” rating in a research note on Tuesday, May 7th. William Blair restated a “market perform” rating on shares of Moderna in a research note on Monday, April 1st. Finally, Oppenheimer increased their price objective on shares of Moderna from $163.00 to $179.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 12th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $134.02.

Moderna Price Performance

MRNA opened at $118.75 on Thursday. The stock has a market cap of $45.51 billion, a P/E ratio of -7.58 and a beta of 1.54. The company has a quick ratio of 3.91, a current ratio of 4.03 and a debt-to-equity ratio of 0.04. Moderna has a 12 month low of $62.55 and a 12 month high of $170.47. The company has a fifty day simple moving average of $134.13 and a 200 day simple moving average of $111.72.

Moderna (NASDAQ:MRNA) last announced its earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.59) by $0.52. The firm had revenue of $167.00 million during the quarter, compared to analyst estimates of $93.26 million. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The company’s revenue for the quarter was down 91.0% compared to the same quarter last year. During the same period in the prior year, the business earned $0.19 EPS. On average, research analysts expect that Moderna will post -7.46 EPS for the current year.

Insider Buying and Selling at Moderna

In other Moderna news, Director Noubar Afeyan sold 15,000 shares of the stock in a transaction dated Wednesday, June 26th. The shares were sold at an average price of $127.22, for a total value of $1,908,300.00. Following the transaction, the director now directly owns 2,284,015 shares of the company’s stock, valued at approximately $290,572,388.30. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, CFO James M. Mock sold 705 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $101.93, for a total transaction of $71,860.65. Following the transaction, the chief financial officer now directly owns 5,048 shares of the company’s stock, valued at $514,542.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 26th. The stock was sold at an average price of $127.22, for a total transaction of $1,908,300.00. Following the transaction, the director now directly owns 2,284,015 shares in the company, valued at $290,572,388.30. The disclosure for this sale can be found here. Insiders have sold a total of 411,255 shares of company stock valued at $56,118,931 in the last three months. 15.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. LPL Financial LLC increased its stake in Moderna by 7.2% in the third quarter. LPL Financial LLC now owns 115,782 shares of the company’s stock valued at $11,959,000 after acquiring an additional 7,811 shares during the last quarter. Mariner LLC increased its stake in Moderna by 5.2% in the third quarter. Mariner LLC now owns 20,242 shares of the company’s stock valued at $2,091,000 after acquiring an additional 996 shares during the last quarter. Stifel Financial Corp increased its stake in Moderna by 19.0% in the third quarter. Stifel Financial Corp now owns 75,871 shares of the company’s stock valued at $7,837,000 after acquiring an additional 12,099 shares during the last quarter. Natixis Advisors L.P. increased its stake in Moderna by 19.9% in the third quarter. Natixis Advisors L.P. now owns 19,924 shares of the company’s stock valued at $2,058,000 after acquiring an additional 3,310 shares during the last quarter. Finally, O Shaughnessy Asset Management LLC increased its stake in Moderna by 34.0% in the third quarter. O Shaughnessy Asset Management LLC now owns 7,664 shares of the company’s stock valued at $792,000 after acquiring an additional 1,945 shares during the last quarter. 75.33% of the stock is owned by institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.